In a previous study, we have shown for the first time that NSCLC patients carrying EGFR mutations in tumor tissue and subjected to first-line treatment with EGFR TKIs, can be strictly monitored in the first days of treatment by repeated blood draws to quantify EGFR mutant alleles in plasma [5]. Here, EGFR is linked to non-small cell lung carcinoma.